Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 103

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 103
---
 TGF - βis pro -fibroticand is directly linked to the propagation of fibrosis. The positive control is an established TGF - βblocker. IL -10is a key driver for the reduction and resolution of inflammation, and NGAL is an important defense for preventing excessive oxidative damage resulting from injury/ongoing inflammation. 65 Development Plan In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -AKI. We expect data from our Phase 1b clinic study in the first half of this year. Revelation will continue evaluating the potential of Gemini in additional preclinical models of CKD to identify optimal dosing conditions and conduct the preclinical testing required for chronic dosing in patients. Gemini-PSI Program Overview Gemini is being evaluated as a potential therapy for the prevention or treatment of post surgical infection. We believe immunologic preconditioning with Gemini prepares the body to resist infection by priming the body’s immune system to respond to pathogen exposure more rapidly. In addition to post surgical infection, we believe Gemini may also have utility for post -burninfection, urinary tract infection (e.g. as a result of hospital -basedor outpatient catheterization), sepsis, and antibiotic -resistantinfection. Revelation is developing Gemini for the prevention of infection through a license agreement with Vanderbilt University. Preclinical studies Multiple preclinical studies have shown that pretreatment with PHAD results in significantly augmented immune response with significantly reduced duration and severity of infection following bacterial challenge with either gram -positiveor gram -negativebacteria as indicated in the following figures. Pretreatment with PHAD Impart Protection from Gram Negative Bacterial Infection 66 Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection Clinical Development Plan During 2024 we conducted a Phase 1 clinical study. Subsequently, safety and biomarker activity data from our Phase 1 clinical study was announced in June of 2024, showing a significant increase in anti -inflammatorycytokines including IL -1RAand IL -10. We are evaluating the next steps to be taken in the development of Gemini -PSI. Gemini-PBI Program Overview The Gemini -PBIprogram is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention of infection in severe burn patients requiring hospitalization. We believe Gemini administration to severe burn patients will augment the patient’s immune response